• Aucun résultat trouvé

Finance and Differential Accumulation in the Global Pharmaceutical Industry

N/A
N/A
Protected

Academic year: 2021

Partager "Finance and Differential Accumulation in the Global Pharmaceutical Industry"

Copied!
16
0
0

Texte intégral

(1)

NOTES DE CONFÉRENCES – DÉCEMBRE 2006

Chaire de Recherche du Canada en Mondialisation, Citoyenneté et Démocratie

http://www.chaire-mcd.ca/

FINANCE AND DIFFERENTIAL

ACCUMULATION IN THE

GLOBAL PHARMACEUTICAL INDUSTRY

Marc-André GAGNON

Chargé de cours à l’Université de Montréal et à l’UQAM, membre de la

Chaire MCD

Ce texte constitue les notes d’une conférence prononcée par l’auteur pour le

CAFCA et présentée au panel « Financialization and Contemporary

Capitalism » du Progressive Economics Forum dans le cadre du congrès de

la Canadian Economics Association, Université Concordia, mai 2006.

(2)

The Nature of Capital in the

Knowledge-Based Economy

Finance and

Differential Accumulation in the

Global Pharmaceutical Industry

By Marc-André Gagnon,

PhD Candidate, York University CAFCA, UQAM

(3)

The Nature of Capital in the Knowledge-Based Economy

Finance and Differential Accumulation in the Global Pharmaceutical Industry

OUTLINE

• Usual Interpretations of Recent Economic Transformations

- New Economy Thesis

- Financialization Thesis

• The Productivity Bias; The Need of a Power Theory of Value

- What is being accumulated?

- Differential Accumulation

• An Illustration with Pharmaceuticals

(4)

Structural Transformations in Advanced

Capitalism: Knowledge or Finance?

1- «New Economy Thesis» (Cognitive Capitalism): Transformations are due

to new intangible sources of production and wealth, chiefly knowledge

and intelligence. Accumulation regime based on creativity and permanent

innovation. (Rifkin, Castells, Matisse-Issys, Negri, Sveiby, Lev)

2- Financialization or «Shareholder Capitalism Thesis»: the rise of

institutional investors created a new regime of growth where firms

restructure the division of labour under new models of corporate

governance to maximize shareholder value. Finance capital captures the

real economy and operates a major income redistribution towards

(5)

0% 100% 200% 300% 400% 500% 600% 700% 800% 900% 1000% 1920 1924 1928 1932 1936 1940 1944 1948 1952 1956 1960 1964 1968 1972 1976 1980 1984 1988 1992 1996 2000 2004

Market Value expressed as % of Book Value Book Value indexed as 100%

The New EconomyThesis:

Intangible Assets as % of Tangible Assets

« Market-to-Book Value » for Dow Jones Industrial Average, 1920-2004

(6)

"Jimbo Index"

Real vs Financial Assets in Canada (as a % of GDP), 1961-2004

Source: Jim Stanford (1999), Statistics Canada (table 380-0016) compiled by Eric Pineault

200% 250% 300% 350% 400% 450% 500% 550% 600% 650% 700% 1961 1963 1965 1967 1969 1971 1973 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 year Real Assets Financial Assets

(7)

100 150 200 250 300 350 400 1947 1950 1953 1956 1959 1962 1965 1968 1971 1974 1977 1980 1983 1986 1989 1992 1995 1998 2001 2004

Output per hour Hourly Compensation

Hourly Productivity and Hourly Real Compensation per Worker

for US Non-Farm Business Sectors Between 1947-2005

(1947=100)

(8)

The Elite takes all

Growth in After Tax Real Income for US Households

According to their Income Level (1947-1979 & 1979-2003)

Source: Congressional Budget Office, Effective Tax Rates (Various years)

116 110 111 114 103 97 52 8,5 17,1 19,8 29,8 41,1 52,6 138,4 0 20 40 60 80 100 120 140 160 Percentiles 1-20 Percentiles 21-40 Percentiles 41-60 Percentiles 61-80 Percentiles 81-95 Percentiles 96-99 Highest Percentile Income Level % 1947-1979 1979-2003

(9)

Problem for both interpretations: Productivity Bias

- Conceit that there is a « real » economy, producing real wealth to which correspond economic values.

- Capital accumulation remains an accumulation of wealth, of useful commodities produced in the past.

Thorstein Veblen’s alternative: dichotomy between Business and Industry

(Theory of Business Enterprise; Absentee Ownership)

- The industry (shared technology by the community) that produces wealth is

inherently a societal process where every product embody the entire history of human knowledge.

- Business (and economics) is about the creation of pecuniary value and the capture of earnings.

- Capital is a claim over putative earning-capacity, a claim not on the usufruct of the past but on future earnings. Capital is only financial capital.

- The corporation is a better form of economic organization to maximize earnings, not by maximizing production but by maximizing the control over productive capacities. - Tangible assets are capitalized in terms of Sabotage capacity; Businessmen thus take the industry hostage and can reclaim a ransom.

- The bulk of any corporation’s capitalization is made of intangible assets, which are any durable earning-capacity (due to any institutional setting, like conventions or state power).

(10)

Shimson Bichler and Jonathan Nitzan’s Differential Accumulation

- Capitalism has to be analyzed as a whole social order, in which accumulation is not an offshoot of production, but, rather, the manifestation of a struggle over the shaping of the social process between dominant groups and the rest of society, as well as between those groups themselves

-Capitalized Earning-Capacity represents a claim, not for a share of the output, but for a share of control over the social process. Capital is the commodification of capitalist power and thus capital accumulation is an accumulation of capitalist power

- Power needs to be measured in differential terms. In the capitalist logic, it is not about the search for maximum profit, it is the search to maximize profits

compared to others, it is to beat the average.

- Capital Accumulation should thus be measured in differential terms (Differential accumulation) by comparing a group’s (or corporation’s) combined capitalization to that of an average unit of capital.

(11)

US World Market Share in Pharma:

Sales: 48%

Production: 29%

R&D: 49%

(12)

0 500 1000 1500 2000 2500 1954 1957 1960 1963 1966 1969 1972 1975 1978 1981 1984 1987 1990 1993 1996 1999 2002 2005 All Fortune 500

Pharma firms in Fortune 500

Big Pharma Differential Accumulation;

Profits of an average US pharmaceutical firm as compared to an average

firm in the Fortune 500 (1954-2005; in millions of constant 1984 US$)

(13)

Are we entering a new era of innovation?

Global Introductions of New Chemical Entities 1961-2005

Sources: 1961-1985: Erika Reis-Arndt (1987) 1986-2005: IMS Lifecycle New Product Focus Database

0 50 100 150 200 250 300 350 400 450 500 1961-1965 1966-1970 1971-1975 1976-1980 1981-1985 1986-1990 1991-1995 1996-2000 2001-2005

(14)

Breadth in Differential Accumulation

BUY-TO-BUILD RATIO

Mergers and Acquisitions in proportion to Gross Capital Formation for US Pharmaceuticals and All US Sectors, 1981-2003 (log scale)

Source: -Bichler and Nitzan (2002)

-for all sectors: BEA and Statistical Abstract of the United States -for pharmaceuticals: OECD Health Data, Thomson Financial

1 10 100 1000 10000 1967 1970 1973 1976 1979 1982 1985 1988 1991 1994 1997 2000 2003 % All US Firms All Pharma US firms

(15)

Depth in Differential Accumulation

Differential Returns on Revenues (ROR) Between Big Pharma and Fortune 500, 1954-2005

Source: Fortune Magazine

0 2 4 6 8 10 12 14 16 18 20 1954 1957 1960 1963 1966 1969 1972 1975 1978 1981 1984 1987 1990 1993 1996 1999 2002 2005 Average ROR of all Fortune 500 Average ROR Pharma Firms

(16)

CONCLUSION:

New economy Thesis and the Financialization Thesis are unable to

account for structural transformations in the Global Pharmaceutical

Business.

By considering capital in terms of power, of control over society, the

differential accumulation analytical framework opens the way to new

hypothesis:

-Structural Competition: Dominant Capitalist groups compete by

transforming willingly the socio-economic institutional settings to

increase their strategic control over the industry and society.

- M&As are a result of externalizing R&D where dominant firms

simply buy back promising results by smaller firms or universities

(Bayh-Dole Act in 1980).

- Differential ROR could maybe be explained by the extension of

intellectual property rights resulting from the activism of American

pharmaceutical companies (especially Pfizer).

Références

Documents relatifs

In particular, I am interested in determining whether an adverse employment history (part-time employment, unemployment, inactivity and years in lower occupations) is related

We interpret this result – the lower efficiency of public investment on output when the ‘Code for Fiscal Stability’ is removed from the sample – as a first, though rough, evidence

In the classic form of the series, a resolved, stand-alone drama is usually organized around one or several recurring characters against the same backdrop.. Seriality is

The user can configure the production planning and order management process, and evaluate how they will perform in various market contexts using the discrete event

Our selection and prioritization procedure is different from the methods used in other studies: In GerES [6,7] see above, a scientific committee conducts the selection of

We observed from tongue contour tracings that the Mid Bunched configuration generally has a lower tongue tip than the Front Bunched one in speakers who present both bunched

L’objectif des études présentées dans cette thèse est de déterminer la disponibilité de certaines substances dans l’environnement, et d’évaluer les effets de la

Our proof of Theorem 1.2.3 uses the p-adic cohomology theory of Dwork, as developed by Adolphson–Sperber [AS89, AS08], relating the zeta function of a member of the family to